HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ER-400583-00

has antineoplastic activity; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aoki, Mika: 1 article (04/2012)
2.	Asano, Makoto: 1 article (04/2012)
3.	Funasaka, Setsuo: 1 article (04/2012)
4.	Ito, Daisuke: 1 article (04/2012)
5.	Kamata, Junichi: 1 article (04/2012)
6.	Kawamura, Takanori: 1 article (04/2012)
7.	Kotake, Yoshihiko: 1 article (04/2012)
8.	Miyazaki, Kazuki: 1 article (04/2012)
9.	Mizui, Yoshiharu: 1 article (04/2012)
10.	Nagao, Satoshi: 1 article (04/2012)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2012 - "Immunohistochemical analysis revealed that ER-400583-00 suppressed the proliferation of cancer cells most prominently in areas distal to the region of blood perfusion, where HIF-1α-expressing hypoxic cancer cells were located. " 04/01/2012 - "The oral administration of 100 mg/kg ER-400583-00 to mice bearing U251 tumor xenografts resulted in a rapid suppression of HIF-1α that persisted for 24 h. "
2.	Glioma (Gliomas) 04/01/2012 - "ER-400583-00 suppressed the production of HIF-1α protein in response to hypoxia, with a half-maximal inhibitory concentration value of 3.7 nM in human U251 glioma cells. "
3.	Hypoxia (Hypoxemia) 04/01/2012 - "ER-400583-00 suppressed the production of HIF-1α protein in response to hypoxia, with a half-maximal inhibitory concentration value of 3.7 nM in human U251 glioma cells. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Oral Administration